PFKFB3 and neoplasm: A recent study showed that blockade of the glycolytic activator PFKFB3 in tumor endothelial cells reduced cancer cell invasion, intravasation, and metastasis, and improved the effect of chemotherapy on primary and metastatic tumors [23].